Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.

Authors :: Bollo L
Guerra T
Bavaro DF
Monno L
Saracino A
Angarano G
Paolicelli D
Trojano M
Iaffaldano P
Source :: Journal of the neurological sciences [J Neurol Sci] 2020 Sep 15; Vol. 416, pp. 117011. Date of Electronic Publication: 2020 Jul 04.
Publication Year :: 2020

Subjects :: Adult
COVID-19 immunology
Disease Progression
Female
Humans
Hydroxybutyrates
Middle Aged
Multiple Sclerosis drug therapy
Nitriles
Seroconversion
COVID-19 complications
Crotonates therapeutic use
Fingolimod Hydrochloride therapeutic use
Immunosuppressive Agents therapeutic use
Multiple Sclerosis complications
SARS-CoV-2 immunology
Toluidines therapeutic use

Full Text Access

Tools